Navigation Links
Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models

- Data presentations at American Association for Cancer Research annual meeting -

PRINCETON, N.J., April 17, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc. today presented preclinical data demonstrating potent anti- tumor activity from two separate studies exploring the efficacy and safety in animal models of anti-CD19 and anti-CD70 antibody-drug conjugates. CD19 and CD70 are both attractive targets for an antibody-drug conjugate approach to cancer therapy. They are expressed on cancer cells with limited normal patterns of expression and are rapidly internalized when bound to antibody. Data from the studies were presented at the American Association for Cancer Research (AACR) annual meeting, April 14-18, 2007, in Los Angeles, CA.

Efficacy study of anti-CD19 antibody drug conjugates in Raji tumor xenograft and systemic model (Abstract #4104)

CD19 is expressed on B cell cancers, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia and acute lymphocytic leukemia. Single dose treatments of a fully human anti-CD19 antibody drug conjugate demonstrated in vivo anti-tumor efficacy leading to the regression of established subcutaneous tumors and systemic tumors in leukemia xenograft models. Anti-CD19 antibody- drug conjugate was well-tolerated and without toxicity in the animal models.

Single, low dose treatment of lymphoma and renal cancer xenografts with human anti-CD70 antibody toxin conjugates, results in long term cures (Abstract #4112)

CD70 is highly expressed in multiple tumor types, including many lymphomas and clear cell renal cancer. Single, low dose treatments of a fully human anti-CD70 antibody drug conjugate demonstrated in vivo anti-tumor efficacy in both preclinical lymphoma and renal cancer xenograft animal models. The anti- CD70 antibody drug conjugate demonstrated a high specificity for its target, a wide therapeutic window of activity, and a favorable toxicity and s afety profiles in larger animals at dose levels which are in excess of an efficacious dose determined in the xenograft models.

"Antibody-drug conjugates exploit the specificity of antibodies and the potency of cytotoxic agents to destroy cancer cells," said Nils Lonberg, PhD, Senior Vice President and Science Director at Medarex. "We believe that the anti-tumor activity from these preclinical antibody-drug conjugate studies is quite compelling, and we look forward to fully exploring the safety and therapeutic activity and application of these programs in future clinical trials."

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with six of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements exp ressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, risks that favorable efficacy and safety results in animal models will not be replicated in humans, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006. There can be no assurance that such development efforts will succeed or that other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


     Laura S. Choi                   Jean Mantuano

     Investor Relations              Corporate Communications (media)

Phone: 609-430-2880, x2216, Phone: 609-430-2880, x2221

CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, ext. 2216, orJean Mantuano, Corporate Communications (media), +1-609-430-2880, ext.2221, both of Medarex, Inc.

Web site: http://www.medarex.com/

Company News On-Call: http://www.prnewswire.com/comp/108265.html/

T icker Symbol: (NASDAQ-NMS:MEDX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point ... strategies to reduce waste, and support renewable energy. They believe this is a crucial ... to find solutions for health issues, and maintain that destroying the environment in the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Today, Bright Pink , a national non-profit organization focusing ... a new CEO. , Bright Pink is proud to announce Katie Thiede as their ... to a new role as Chairman of the Board and launched a national search ...
(Date:4/24/2017)... ... , ... The John P. McGovern Museum of Health and Medical Science is ... cognitive health, and share results with their physicians. Members and guests can sign up ... , BrainCheck founder, Dr. David Eagleman, formerly at Baylor College of Medicine and now ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... industry, announces the company’s VideoMedicine mobile platform has launched Quick Care, a new ... a day, Quick Care provides patients with the option to request and begin ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
Breaking Medicine News(10 mins):